Cavendish NanoTherapeutics Ltd

Fulbourn, United Kingdom

Cavendish NanoTherapeutics Ltd

Fulbourn, United Kingdom
SEARCH FILTERS
Time filter
Source Type

Orel V.,National Cancer Institute | Shevchenko A.,NASU G.V. Kurdyumov Institute For Metal Physics | Romanov A.,National Cancer Institute | Tselepi M.,University of Cambridge | And 7 more authors.
Nanomedicine: Nanotechnology, Biology, and Medicine | Year: 2015

We present a technology and magneto-mechanical milling chamber for the magneto-mechano-chemical synthesis (MMCS) of magneto-sensitive complex nanoparticles (MNC) comprising nanoparticles Fe3O4 and anticancer drug doxorubicin (DOXO). Magnetic properties of MNC were studied with vibrating magnetometer and electron paramagnetic resonance. Under the influence of mechano-chemical and MMCS, the complex show a hysteresis curve, which is typical for soft ferromagnetic materials. We also demonstrate that Lewis lung carcinoma had a hysteresis loop typical for a weak soft ferromagnet in contrast to surrounding tissues, which were diamagnetic. Combined action of constant magnetic field and radio frequency moderate inductive hyperthermia (RFH) below 40°C and MNC was found to induce greater antitumor and antimetastatic effects as compared to conventional DOXO. Radiospectroscopy shows minimal activity of FeS-protein electron transport chain of mitochondria, and an increase in the content of non-heme iron complexes with nitric oxide in the tumor tissues under the influence of RFH and MNC. From the Clinical Editor: This study reports on the top-down synthesis of magneto-sensitive complex nanoparticles comprised of Fe3O4 nanoparticles and doxorubicin. Authors also found that Lewis lung carcinoma had a hysteresis loop typical for a weak soft ferromagnet in contrast to surrounding tissues, which were diamagnetic. Combined action of constant magnetic field and radio frequency induced moderate hyperthermia induced both antitumor and antimetastatic effects greater than conventional DOX alone. © 2015 Elsevier Inc.


Orel V.E.,National Cancer Institute Medical Physics & Bioengineering Research Laboratory | Mitrelias T.,University of Cambridge | Mitrelias T.,Cavendish NanoTherapeutics Ltd | Tselepi M.,University of Cambridge | And 7 more authors.
IFMBE Proceedings | Year: 2015

We proposed a new technology of nanotheranostics that is combination of magnetic resonance therapy and chemotherapy during moderate hyperthermia below 40 ºC inside tumor with diagnostics by magnetic resonance imaging. As nanotheranostics agent the multifunctional magnetosensitive nanocomplex consisted of nanoparticles containing Fe3O4 with diameters < 50 nm and antitumor drug doxorubicin was used. The synthesis of multifunctional magneto-sensitive nanocomplex was performed in a magnetomechanical reactor. We conducted a detailed imaging study of transplanted Guerin’s carcinoma in rats during treatment with magnetic nanotherapy. We showed that treatment with magneto-mechano-chemically synthesized magnetosensitive nanocomplexes based on Fe3O4 nanoparticles conjugated with the antitumor agent doxorubicin and followed by irradiation with local electromagnetic irradiation resulted in a better outcome than treatment with conventional doxorubicin or treatment with magnetic nanocomplexes without electromagnetic irradiation. An analysis of magnetic resonance images obtained over time showed that the application of local electromagnetic irradiation did not alter the position of magnetic nanocomplexes in the tumor. © Springer International Publishing Switzerland 2015.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Innovation Voucher | Award Amount: 5.00K | Year: 2013

The objective is to adapt an existing technology, in order to develop systems to screen food/water samples in a multiplexed manner for the presence of pathogens, i.e., performing many different chemical tests in parallel. Multiplexed diagnostics enables more analytical tests to be performed concurrently, from a single sample, using a handheld device, at reduced time and cost. Cavendish NanoTherapeutics (CNT) is developing a platform technology for healthcare (targeted cancer treatment) based on magnetic nanoparticles synthesised by a proprietary method, which enables to tune their physicochemical properties (e.g. increased magnetisation, sizes, etc) to specific applications. The idea proposed is that nanoparticles can be encoded with magnetic barcodes, so that each nanoparticle is associated with a single chemical test. Cambridge BioMagnetics (CBM) has developed the magnetic encoding technology and CNT needs CBM’s technology to develop the test devices for the agricultural industry.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Smart - Development of Prototype | Award Amount: 170.23K | Year: 2011

Cancer remains the second leading cause of deaths worldwide and every year, more than 8 million people die of it, while in the U.S. alone there are over 1.5 million new diagnoses. In the USA alone the overall cost to the health care system for treatment and support of cancer patients is $200 billion per year. Cavendish NanoTherapeutics (CNT) is developing advanced treatment systems aimed at the targeted eradication of cancer tumours. CNT’s proprietary systems are based on magnetic nanotechnology and utilize nanoparticles loaded with anticancer drugs and guided towards the tumour site to selectively destroy it, in conjunction with externally applied electromagnetic excitation. Our trials have demonstrated significant effects in the reduction of the size of a tumour and a 50% - 300% increase in the survival rates (on average) of patients with various types of cancer. For example, we have demonstrated a tripling in the survival rates of patients with stage IIIA lung cancer, when our treatment protocol is applied in conjunction with traditional therapies. The key objectives of the TSB-funded project are: (i) to further develop the system that induces regional hyperthermia (MagTherm) and to proceed with CE certification and gaining approval from regulatory bodies, (ii) to refine the development of the second generation technology based on the use of magnetic nanoparticles for targeted eradication of cancer cells, (iii) to set up a reactor-chamber for the production of nanoparticles with improved physical and biochemical properties and to (iv) fully characterise the nanoparticles together with the systems used for the generation of the external electromagnetic irradiation (Magtherm system). CNT is as a spin off company from the Cavendish Laboratory, University of Cambridge and benefits from access to facilities and expertise at Cambridge and at the National Cancer Institute, Kiev, with which a collaboration has been established.

Loading Cavendish NanoTherapeutics Ltd collaborators
Loading Cavendish NanoTherapeutics Ltd collaborators